Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction

@article{GoldmanRakic2004TargetingTD,
  title={Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction},
  author={Patricia S. Goldman-Rakic and Stacy A. Castner and Torgny H. Svensson and Larry J. Siever and Graham V. Williams},
  journal={Psychopharmacology},
  year={2004},
  volume={174},
  pages={3-16}
}
Background and rationaleReinstatement of the function of working memory, the cardinal cognitive process essential for human reasoning and judgment, is potentially the most intractable problem for the treatment of schizophrenia. Since deficits in working memory are associated with dopamine dysregulation and altered D1 receptor signaling within prefrontal cortex, we present the case for targeting novel drug therapies towards enhancing prefrontal D1 stimulation for the amelioration of the… Expand
Dopamine, cognitive function, and gamma oscillations: role of D4 receptors
TLDR
The current state of knowledge of D4R functions in the PFC and hippocampus, two major brain areas implicated in SCZ, is reviewed, with special emphasis given to studies focusing on the potential role of D 4Rs in modulating GABAergic transmission and to an emerging concept of a close synergistic relationship between dopamine/D4R and neuregulin/ErbB4 signaling pathways. Expand
Insights into the Role of Dopamine Receptor Systems in Learning and Memory
TLDR
Strong evidence is provided that dopamine is part of the network that plays a very important role in cognitive function, and that although multiple dopamine receptor subtypes contribute to different aspects of learning and memory, the D1 receptor seems to play a more prominent role in mediating plasticity and specific aspects of cognitive function. Expand
Targeting Prefrontal Cortical Dopamine D1 and N-Methyl-D-Aspartate Receptor Interactions in Schizophrenia Treatment
  • C. Yang, Long Chen
  • Psychology, Medicine
  • The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry
  • 2005
TLDR
Some of the latest findings on the cellular mechanisms that underlie D1-NMDA receptor interactions have provided potential therapeutic strategies that aim to functionally up-regulate D1 and/or NMDA receptor safely via selective activation of D1 receptors or coagonist activation of NMDA receptors through blockade of the glycine transporter-1. Expand
The dopamine dysfunction in schizophrenia revisited: new insights into topography and course.
TLDR
Evidence from translational research suggests that dopaminergic excess may be present in the prodromal phase, and may by itself, be an early pathogenic condition, leading to irreversible cortical dysfunction. Expand
Chapter DOPAMINERGIC AND GLUTAMATERGIC DYSFUNCTIONS IN THE NEUROPATHOPHYSIOLOGY OF SCHIZOPHRENIA
Schizophrenia is a devastating mental disorder that affects almost 1% of the human population. Although the etiology and fundamental pathological processes associated with schizophrenia remainExpand
Under the curve: Critical issues for elucidating D1 receptor function in working memory
TLDR
The hypothesis that the window of optimal dopamine signaling changes on a behavioral time-scale, dependent upon current cognitive demands and local neuronal activity as well as long-term alterations in signaling pathways and gene expression is explored. Expand
The neurobiology of cognition in schizophrenia.
  • C. Tamminga
  • Psychology, Medicine
  • The Journal of clinical psychiatry
  • 2006
TLDR
Domain treatment of schizophrenia is a new method of treating schizophrenia that involves treating a single domain of dysfunction at a time and several putative molecular targets for treating cognition in schizophrenia show promise. Expand
Attention and Working Memory: Animal Models for Cognitive Symptoms of Schizophrenia – Studies on D2-Like Receptor Knockout Mice
The ability of humans and other higher vertebrates to implement and orchestrate behavioral strategies that are geared towards defined goals is governed by fundamental cognitive functions ofExpand
Cell-based therapies for the treatment of schizophrenia
TLDR
The evidence for interneuron pathology in schizophrenia is discussed, recent advances in the understanding of interneeuron development are reviewed, and how these advances have allowed us to test the therapeutic value ofInterneuron transplants in multiple preclinical models of schizophrenia is explored. Expand
Characterization of dopamine D 1 receptor agonists in vivo-Implications for the treatment of schizophrenia and Parkinson ’ s disease
Dopamine is fundamental in human behavior for movement, cognition and reward. A dysfunctional dopamine system is implicated in several neurological and psychiatric disorders such as Parkinson’sExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 220 REFERENCES
Prefrontal Dopamine D1 Receptors and Working Memory in Schizophrenia
TLDR
Findings confirm that alteration of DLPFC D1 receptor transmission is involved in working memory deficits presented by patients with schizophrenia. Expand
The relationship between dorsolateral prefrontal N-acetylaspartate measures and striatal dopamine activity in schizophrenia∗ ∗ See accompanying Editorial, in this issue.
TLDR
Direct relationships between putative neuronal pathology in dorsolateral prefrontal cortex and striatal dopamine activity in human and nonhuman primates and implicate a mechanism for dopamine dysregulation in schizophrenia are demonstrated. Expand
The Relationship between Dorsolateral Prefrontal Neuronal N-Acetylaspartate and Evoked Release of Striatal Dopamine in Schizophrenia
TLDR
The hypothesis that in schizophrenia neuronal pathology of dorsolateral prefrontal cortex is directly related to abnormal subcortical dopamine function is supported. Expand
Dopamine in schizophrenia: a review and reconceptualization.
TLDR
The authors hypothesize that schizophrenia is characterized by abnormally low prefrontal dopamine activity leading to excessive dopamine activity in mesolimbic dopamine neurons (causing positive symptoms) and has important implications for treatment of schizophrenia and schizophrenia spectrum disorders. Expand
Down-regulation of the D1 and D5 dopamine receptors in the primate prefrontal cortex by chronic treatment with antipsychotic drugs.
TLDR
A reduction in the levels of prefrontal cortical dopamine receptors of the D1 class may be an obligatory consequence of D2 receptor antagonism and thus may be a pharmacological property of antipsychotic drugs. Expand
Evidence for decreased DARPP-32 in the prefrontal cortex of patients with schizophrenia.
TLDR
These findings are consistent with a selective reduction in DARPP-32 levels in schizophrenic subjects, and may play an important role in the pathophysiological changes in dopamine and glutamate function reported in patients with schizophrenia. Expand
Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET
TLDR
Although no differences were observed in the striatum relative to control subjects, binding of radioligand to D1R was reduced in the prefrontal cortex of schizophrenics, and this reduction was related to the severity of the negative symptoms and to poor performance in the Wisconsin Card Sorting Test. Expand
Up-regulation of the D1 dopamine receptor-interacting protein, calcyon, in patients with schizophrenia.
TLDR
These findings provide the first evidence that abnormalities in the dopamine system of patients with schizophrenia may lie in altered levels of dopamine receptor-interacting proteins. Expand
The cerebral cortex: a case for a common site of action of antipsychotics.
TLDR
Evidence supporting the cerebral cortex as a pivotal site for these mechanisms underlying the action of antipsychotics and balancing the opposing actions of dopamine D1 and D2 receptor regulation may hold the key to optimal drug therapy and to understanding the pathophysiology of schizophrenia. Expand
Increased dopamine transmission in schizophrenia: relationship to illness phases
TLDR
A hyperdopaminergic state is present in schizophrenia during the initial episode and subsequent relapses, but not in periods of remission, which has important consequences for the development of new treatment strategies for the remission phase. Expand
...
1
2
3
4
5
...